Heart Disease & Cardiology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

This global Phase III trial is testing a new combination treatment of baxdrostat and dapagliflozin for adults with heart failure and type 2 diabetes. The goal is to see if this combination can reduce heart failure events and lower the risk of death related to heart and blood vessel problems. If successful, it could offer a new treatment option for people aged 40 and older with heart conditions and other risk factors.

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

This Phase 3 trial focuses on the long-term safety of pelacarsen, a drug for people with cardiovascular disease who have high levels of a substance called Lipoprotein(a). The study follows patients who completed an earlier trial to see how well they tolerate pelacarsen over time. This could help provide a new way to manage heart disease risk for patients worldwide.

The SELEQT-HF Study Evaluating Selenium and CoQ10 Supplementation in Heart Failure

This study is investigating whether adding selenium and CoQ10 supplements to standard heart failure treatments can improve health outcomes. The trial will enroll 1,100 patients in the Netherlands and aims to find out if these natural supplements can reduce heart failure events and deaths. This approach may provide a simple and safe addition to existing therapies if proven effective.

Pre-arrival Instructions Effect on Bystander Cardiopulmonary Resuscitation (CPR)

This completed study looked at whether giving instructions to bystanders before emergency services arrive can increase the number of people performing CPR on someone having a cardiac arrest outside of the hospital. Results are available and suggest that guiding bystanders could improve survival chances by encouraging quicker assistance during these emergencies.

The Effectiveness of a Theory-driven Behavioral Change Intervention on Sedentary Behavior in Individuals With Coronary Heart Disease

This trial is testing a program designed to help people with coronary heart disease spend less time sitting and move more. The intervention includes face-to-face and phone sessions over three months. If successful, this approach could offer a non-medication way to improve heart health by encouraging healthier daily habits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.